Transurethral application of Alprostadil with MUSE(TM) (Medicated Urethral System for Erection). Actual overview and personal experiences;Transurethrale Alprostadilapplikation mit MUSE(TM) ('Medicated Urethral System for Erection'). Aktuelle ubersicht und eigene erfahrungen

Urologe - Ausgabe A

Volumn 37, Issue 4, 1998, Pages 410-416

  Porst, H ^a  

^a Urologische Praxis Hamburg ^*  (Germany)

Author keywords

Alprostadil; Erectile dysfunction; MUSE(TM); Self injection therapy; Transurethral therapy

Indexed keywords

PROSTAGLANDIN E1; VASODILATOR AGENT;

ADULT; ARTICLE; BLEEDING; COITUS; DRUG EFFICACY; HUMAN; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PAIN; PRIAPISM; SYNCOPE; TRANSURETHRAL DRUG ADMINISTRATION; URETHRA STRICTURE; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; INJECTION; PENIS; PENIS ERECTION; REVIEW; VASCULARIZATION;

ALPROSTADIL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; INJECTIONS; MALE; PENILE ERECTION; PENIS; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASODILATOR AGENTS;

EID: 0031853461     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050199     Document Type: Article

References (28)

1. Barrett DM, Nehra A, King BF (1997) Hemodynamic interpretation following redosing during duplex doppler ultrasonography: is there a change in diagnosis? J Urol 157 [Suppl] 179: Abs 695
2. Costabile RA, Govier FE, Ferrigni RG, McVary KT, Shabsigh R, Nemo KJ, Tam PY, Spivack AP on behalf of the VIVUS-MUSE Study Group (1997) Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 157 [Suppl]: 364, Abs 1424
3. Garceau RJ, Zhang JX, Jen L (1996) Dose-response studies of intracavernous injection therapy with Alprostadil in Asian and Australian men with erectile dysfunction. Curr Ther Res 57: 50-61
4. Gesundheit N, Peterson CA, Cowley C, Azzam SM, Owen JS, Balabanow G, Baumeister A, Häring N (1997) The pharmakokinetics of transurethral Alprostadil (Prostaglandin E1) in men with erectile dysfunction. J Urol 157 [Suppl]: 259, Abs 1013
5. 0 nach intracavernöser Injektion bei Patienten mit erektiler Dysfunktion. Urologe A 34 [Suppl] 1: 13
6. Kropman RF, von Oostayen JA, Zwinderman KH, Lycklama à Nijeholt GAB, Schipper J, Meinhardt W (1994) Relation of intracorporal pressure and end-diastolic velocity during duplexdopplersonography in the evaluation of veno-occlusive dysfunction. Int J Impotence Res 6: 125-126
7. Lea AP, Bryson HM, Balfour JA (1996) Intracavernous Alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging Jan 8: 56-74
8. O'Leary MP, Barada JH, Costabile RA, Fallon B, Fischman JJ, Padma-Nathan H, Romas NA, Spivack AP, Tam PY for the MUSE® Study Group (1996) Transurethral Alprostadil improves quality of life for patients and partners. Int J Impotence Res 8: A68
9. Lewis RW, Brendler C, Burnett A, Ferrigni RG, Hellstrom WJG, Padma-Nathan H, Romas NA, Shabsigh R, Stamey TA,Young PR, Stephens D, Peterson CA, Gesundheit N (1997) A comparison of transurethral Alprostadil and Alprostadil/ Prazosin combinations for the treatment of erectile dyfunction (ED). J Urol Vol 157 [Suppl]: 181, Abs 703
10. Linet OI, Ogrinc FG and Alprostadil Study Group (1996) Efficacy and safety of intracavemosal Alprostadil in men with erectile dysfunction. N Engl J Med 334: 873-877
11. Linet OI, Ogrinc FG (1996) Penile fibrosis during 18 months of intracavernosal therapy with Alprostadil (Caverject®). Int J Impotence Res 8: D85
12. Merckx LA, de Bruyne RMG, Goes E, Derde MP, Keuppens F (1992) The value of dynamic color duplex scanning in the diagnosis of venogenic impotence. J Urol 148: 318-320
13. Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH (1990) Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 156: 2007-2011
14. 1 stimulation in the diagnosis of arteriogenic impotence. Eur Urol 24: 36-42
15. Padma-Nathan H, Keller T, Poppiti R, Lue T, Tam P, Place V (1994) Hemodynamic effects of intraurethral Alprostadil: the medicated urethral system for erection (MUSE®). J Urol 151: 345, A 469
16. Padma-Nathan H, Bennett A, Gesundheit N, Hellstrom W, Henry D, Lue T, Morley I, Peterson C, Prendergast J, Tam P, Teresi A, Place V and the VIVUS Study Group (1995) Treatment of erectile dysfunction by the medicated urethral system for erection (MUSE®). J Urol 153 [Suppl]: 472, Abs 975
17. - Study Group (1997) Treatment of men with erectile dysfunction with transurethral Alprostadil. N Engl J Med 336: 1-7
18. Padma-Nathan H, Linet O, Sheu W (1997) The impact on return of spontaneous erections of short term Alprostadil therapy post nerve sparing radical prostatectomy. J Urol 157 [Suppl] 363: Abs 1422
19. Padma-Nathan H, Tam PY, Place VA, Aboseif SRG, Lue TF (1997) Improved erectile response to transurethral alprostadil by use of a novel, adjustable penile band. J Urol 157 [Suppl]: 181, Abs 704
20. Peterson CA, Crowley A, Dzerk A, Gesundheit N, Hellstrom WIG, Lee JW, Sikka SC, Place VA and the VIVUS-MUSE® Study group (1993) The medicated urethral system for erection: does transurethral Alprostadil affect the concentration of prostaglandins in human ejaculate or the viability and motiliy of human sperm. European Urology Abstract of 12 Congress of the European Ass. of Urology Sep 1-4 Paris, p 158, Abs 568
21. Porst H (1993) Die Duplexsonographie des Penis. Wertigkeit eines neuen Diagnostikums anhand von über 1000 Patienten. Urologe [A] 32: 242-249
22. 1: long-term results of an international multicenter study according to the GCP-Standard Int J Impotence Res 6 [Suppl] 1: D108
23. 1 after 4 years of follow-up. Int J Impotence Res 8: 151, D118
24. 1 in erectile failure: a survey of worldwide experience. J Urol 155: 802-815
25. Porst H, Abbou CC, Amar E, Devaux P, Klam TA, Gesundheit N, Hall M, Lycklama à Nijeholt AAB, Lynch SF, Morgan RJ, Muller SC, Pryor JP, Ryan PC, Williams G, Witzsch UKF, Place VA and the European VIVUS-MUSE® Study Group (1996) Transurethral Alpostadil for the treatment of chronic erectile dynfnction: the European experience. Int J Impotence Res 8: 131, D35
26. Spivack AP, Peterson CA, Cowley C, Hall M, Nemo KJ, Stephens D, Tam PY, Todd CK, Place VA, Gesundheit N on behalf of the VIVUS-MUSE Study Group (1997) Long-term safety profile of trans-urethral alprostadil for the treatment of erectile dysfunction. J Urol 157 [Suppl]. 203, Abs 792
27. Vardi Y, Saenz de Tejada I (1996) Transfer of vasodilator drugs from the glans and corpus spongiosum to the corpora cavernosa. Int J Impotence Res 8: 130, D33
28. Wilke RJ, Glick HA, McCarron TJ, Erder MH, Althof SE, Linet OI (1996) Quality of life effects of Al-prostadil therapy for erectile dynsfunction in the U. S. and Europe. Int J Impotence Res 8: 113 A58